VIDEO: Durability of bispecific antibodies highlighted at ASH
Click Here to Manage Email Alerts
In this video, Stephen M. Ansell, MD, PhD, discusses research on the durability of bispecific antibodies, presented at ASH Annual Meeting and Exposition.
"We're really seeing benefit that is durable in some cases where the bispecific antibody completed a course and stopped, and patients were just followed,” professor of medicine in the department of hematology at Mayo Clinic, Minnesota, said, adding that many of those patients remain in remission.
"This really opens up a field that is going to be very interesting in the future, and that is balancing bispecific antibodies and [chimeric antigen receptor (CAR) T-cell therapies where they're in a very similar space to determine which may be your best strategy — because both of them are highly effective and both of them now are showing to be very durable.”
Collapse
Healio Interviews
Click Here to Manage Email Alerts